Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI
Hsiao-Ying Wey · NCT06763172
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–45 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 4
- Target enrollment
- 12
- US sites recruiting
- 1
- Study start
- May 17, 2023
- Record last updated
- January 9, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This research study aims to determine whether and how caffeine intake affects learning process through reward feedback compared to placebo. The data acquired from this study would improve our understanding on the consequence and mechanism of caffeine intake in the aspect of learning process.
Participants will perform a reinforcement learning task (i.e. Probabilistic Selection Task) and a motor inhibition task (i.e. Go/NoGo task) in a brain scan. The scan will be done with the Siemens Biograph mMR positron emission tomography (PET)/ magnetic resonance imaging (MRI) 3 Tesla scanner. The PET allows us to see the changes in the "reward signals" - dopamine - in the brain using a radioactive dye called [11C]Raclopride. The MRI, on the other hand, enables us to take detailed pictures of the brain activities during cognitive tasks using a high-powered magnet. Reviewing these pictures will help us understand the influence of caffeine on reward signals and brain activities during the learning process.
Being studied: Caffeine (200 mg); Placebo
Conditions: Healthy; Caffeine; Adenosine; Dopamine D2/3 Receptor Availability
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age ≥ 18 and ≤ 45.
- Habitual caffeine intake ≥ 100 mg and ≤ 450 mg daily.
- Non-smokers.
- Clinically healthy.
- Have normal vision or corrected to normal vision.
Exclusion Criteria
- Pregnant or lactating women.
- Women using hormonal contraceptives.
- BMI \< 18.5 or > 29.9
- Sleep disturbance or extreme chronotype.
- Urine test positive on one of the following substances: benzoylecgonine, morphine, d-Methamphetamine, d-Amphetamine, Benzodiazepines, Secobarbital, Methadone, Buprenorphine Glucuronide, Nortriptyline, MDMA, Oxycodone, PCP, Propoxyphene, and Cannabis/THC
- Diagnosis of depression, anxiety, psychosis, or neurologic disorders in the last 5 years.
- Heart or cardiovascular diseases.
- Diabetes or other metabolic diseases.
- Under chronic medications, for instance, painkiller and steroid.
- Allergy to lactose (main ingredient of blank control dose)
- Incapable to operate the tasks or comprehend the study information in English.
General MRI and PET safety exclusion criteria for all subjects:
- Metallic foreign bodies such as cardiac pacemakers, perfusion pumps, aneurysm clips, metallic tattoos anywhere on the body, tattoos near the eye.
- Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions
- Inability to lie flat on scanner bed for about 90 min as assessed by physical examination and medical history (e.g. arthritis)
- Recent exposure to radiation (i.e., PET from other research studies) that, when combined with this study, would be above the allowable limits
- Pregnancy or breastfeeding: A negative serum or urine pregnancy test is required on the day of the PET procedure
- Body weight of > 300 lbs (weight limit of the MRI scanner table)
Recruiting US locations
Athinoula A. Martinos Center for Biomedical Imaging
Charlestown, MA 02129
Site contact: Hsiao-Ying Wey, PhD · 617-724-1384 · hsiaoying.wey@mgh.harvard.edu
Study contacts (from the official record)
- Hsiao-Ying Wey, PhD · 6177241384 · hsiaoying.wey@mgh.harvard.edu
Similar studies in Massachusetts
All healthy volunteers studies in Massachusetts →- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
Mabylon AG
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
- Location
- Boston, MA + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Boston, MA + 49 other US sites
- Eligibility basics
- Ages 60+